February 08, 2012

Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex

 

Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex

Paris, France and New York, New York – February 8, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that Apotex has made payment in the amount of $442,209,362 to satisfy the damages ruling of the Plavix® (clopidogrel bisulfate) patent infringement case against Apotex. This payment, which follows the decision of the U.S. Court of Appeals for the Federal Circuit in October 2011 upholding the payment of damages to the companies by Apotex, represents the final phase of the Plavix® patent litigation between the companies and Apotex, which was initiated in March 21, 2002. Sanofi and Bristol-Myers Squibb were also awarded $1,258,682 in post-judgment interest and $900,000 in costs in addition to the damages award.